HMA-venetoclax yields 50% overall response rate in relapsed/refractory AML meta-analysis
Combination therapy shows response in relapsed leukemia
This systematic review and meta-analysis of 2289 adults with relapsed/refractory acute myeloid leukemia found that hypomethylating agents pl…
For adults with relapsed leukemia, combining two drugs led to a 50% response rate, offering a potential new option for a tough situation.
Systematic review and meta-analysis on NY-ESO-1 expression in triple-negative breast cancer
A Hidden Protein in Aggressive Breast Cancer May Unlock New Treatments
This meta-analysis of 12 studies in 1,545 TNBC patients found a pooled NY-ESO-1 expression prevalence of 16.1%. The authors note substantial…
A protein found in about one in six triple-negative breast cancers could open the door to immune-based treatments that target cancer cells w…
Clinical features and treatment responses in 40 male patients with VEXAS syndrome
HMA treatment shows promise for VEXAS syndrome patients
This retrospective multicenter study of 40 male patients with VEXAS syndrome evaluated clinical features and various treatment responses.
New data on VEXAS syndrome suggests that hypomethylating agents may help improve clinical and biological responses in men.
Long-course venetoclax with hypomethylating agents in unfit AML patients shows stable efficacy and MRD prognostic value
Frail Leukemia Patients See Better Results With New Blood Monitoring
This single-center retrospective analysis evaluated long-course venetoclax combined with hypomethylating agents in unfit AML patients.
A new look at blood tests shows how well frail leukemia patients respond to standard treatment.
Meta-analysis finds HMA plus venetoclax yields 66% CR/CRi rate in younger, fit AML patients
Analysis finds promising results for leukemia treatment in younger patients
A meta-analysis of 429 younger, fit AML patients found HMA plus venetoclax yielded a 66% CR/CRi rate and 75% 1-year OS.
Younger acute myeloid leukemia patients treated with a specific drug combination achieved 75% one-year survival and 66% complete remission r…